Advertisement

Endocrine

, Volume 61, Issue 3, pp 440–446 | Cite as

Natural history and clinical characteristics of 50 patients with Wolfram syndrome

  • Gema Esteban BuenoEmail author
  • Dyanne Ruiz-Castañeda
  • Javier Ruiz Martínez
  • Manuel Romero Muñoz
  • Pedro Carrillo Alascio
Original Article

Abstract

Purpose

To describe clinical characteristics of diabetes mellitus (DM) in a group of patients with Wolfram Syndrome (WS).

Methods

Descriptive, cross-sectional observational design. The sample consisted of 50 patients diagnosed with WS. Clinical criteria contributing to WS diagnosis were analyzed: diabetes mellitus (DM), optic nerve atrophy (OA), sensorineural deafness, urological and neurological dysfunction, among others. These parameters were assessed according to their presence/absence, age of onset, and various clinical-analytical parameters.

Results

All the patients studied presented DM and OA, with a mean age of onset of 5.4 ± .9 (1–14) years and 9 ± .9 (1–16) years, respectively. The remaining criteria were present with a variable frequency: 77% had diabetes insipidus, 66.7% auditory alterations, 77.8% neurogenic bladder, 61.1% neurological involvement, and 27.8% hypogonadism. A 16.7% of the patients had positive albuminuria (urinary albumin/creatinine ratio > 30 mg/g) and 72.2% had hyporreflexia. There were no significant differences in the age of diagnosis nor of the presence of different pathologies according to sex.

Conclusions

The early presence of a non-autoimmune insulin dependent DM, should alert us of an “infrequent” diabetes syndrome. Wolfram’s presumptive diagnosis could be established if juvenile-onset DM occurs concomitantly with OA, and this visual impairment is not attributable to diabetic retinopathy. Despite the long period of evolution of DM and altered values of HbA1c, the prevalence of microvascular complications in the sample are low.

Keywords

Wolfram syndrome Diabetes mellitus Optic atrophy Sensorineural deafness Neurodegeneration DIDMOAD 

Notes

Acknowledgements

We sincerely thank the patients and families of the Association for Research and Help for Wolfram Syndrome who have agreed to participate in this study. To Dr. Timothy G. Barrett for his invaluable contributions in the present manuscript, to the professionals that make up the Multidisciplinary Team of Wolfram Syndrome (Mónica Ruano Garcia (MF y C), Luisa M. Botella Cubells (Inv. genética), Luz María Martín Egea (psicóloga), Fernando Sánchez García (pediatría) Maria Alharilla Montilla Ibáñez. (ORL), Nicolas Fernandez Fernandez. (ORL), Jose Ignacio Abad Vivas-Pérez (urologia), Belén Gomez Navarro (OFT.), M. Teresa Belmonte García (DUE)).

Authors contribution

All authors contributed towards preparation of this manuscript.

Funding

This study was funded by the Consejería de Salud de la Junta de Andalucía, Spain. (Ref. PI-0410-2016).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    F. Khanim, J. Kirk, F. Latif, T.G. Barrett, WFS1/wolframin mutations, Wolfram syndrome, and associated diseases. Hum. Mutat. 17, 357–67 (2001).  https://doi.org/10.1002/humu.1110 CrossRefPubMedGoogle Scholar
  2. 2.
    T. Barrett, S. Bundey, A. Macleod, Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 346, 1458–63 (1995).  https://doi.org/10.1016/S0140-6736(95)92473-6 CrossRefPubMedGoogle Scholar
  3. 3.
    S. Amr, C. Heisey, M. Zhang et al. A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2. Am. J. Hum. Genet. 81, 673–83 (2007).  https://doi.org/10.1086/520961 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    F. Urano, Wolfram syndrome: diagnosis, management, and treatment. Curr. Diabetes Rep. 16, 6 (2016).  https://doi.org/10.1007/s11892-015-0702-6 CrossRefGoogle Scholar
  5. 5.
    S. Kumar, Wolfram syndrome: important implications for pediatricians and pediatric endocrinologists. Pediatr. Diabetes 11, 28–37 (2010)CrossRefPubMedGoogle Scholar
  6. 6.
    P. Garcia, A. Leal, F. Villamil et al. Síndrome de DIDMOADUA (DIDMOAD). Estudio de tres familias con 5 nuevos casos. Diferencias con la diabetes mellitus insulindependiente clásica. Med. Clin. 85, 486–90 (1985)Google Scholar
  7. 7.
    K. Homa, A. Stefański, A. Zmysłowska, P. Molęda, M. Bryśkiewicz, L. Majkowska, False diagnosis of type 1 diabetes mellitus and its complications in Wolfram syndrome–is it the reason for the low number of reported cases of this abnormality?. Endokrynol. Pol. 65, 398–400 (2014).  https://doi.org/10.5603/EP.2014.0055 CrossRefPubMedGoogle Scholar
  8. 8.
    G. Boutzios, S. Livadas, E. Marinakis, N. Opie, F. Economou, E. Diamanti-Kandarakis, Endocrine and metabolic aspects of the Wolfram syndrome. Endocrine 40, 10–13 (2011).  https://doi.org/10.1007/s12020-011-9505-y CrossRefPubMedGoogle Scholar
  9. 9.
    L. Paris, Y. Usui, J. Serino, J. Sá, M. Friedlander, A challenging form of non-autoimmune insulin-dependent diabetes in a wolfram syndrome patient with a novel sequence variant. J. Diabetes Metab. 6, 1–5 (2015).  https://doi.org/10.4172/2155-6156.1000561 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    G. Esteban, F. Gómez, Manifestaciones clínicas y retraso diagnóstico en el síndrome de Wolfram. Rev. Clínica Esp. 206, 332–335 (2006).  https://doi.org/10.1157/13090481 CrossRefGoogle Scholar
  11. 11.
    G. Esteban, M. Ruano, I. Motero, M. Soler, I. Balaguer, in Las enfermedades raras. Desde una perspectiva bio-psico-social, ed. by (ASUNIVEP)EAU de E y P (Acercamiento Multidisciplinar a La Salud En El Envejecimiento, 2013), pp. 199–204.Google Scholar
  12. 12.
    G. Esteban, M. Ruano, S. Durán, Analizan la calidad de vida de los padres de enfermos con síndrome de Wolfram. Salud Cienc. 17, 444–8 (2010)Google Scholar
  13. 13.
    G. Esteban, Aproximación al tratamiento integral del Síndrome de Wolfram. Aspectos biopsicosociales. (2015)Google Scholar
  14. 14.
    L. Rigoli, G. DʼAnnunzio, in Diabetes in Wolfram Syndrome: Update of Clinical and Genetic Aspects, ed. by F. Barbetti, L. Ghizzoni, F. Guaraldi (Karger Publishers, 2017) pp. 69–77Google Scholar
  15. 15.
    A. Karasik, C. O’Hara, S. Srikanta, et al. Genetically Programmed Selective Islet β-Cell Loss in Diabetic Subjects With Wolfram’s Syndrome. Diabetes Care 12, (1989).  https://doi.org/10.2337/diacare.12.2.135
  16. 16.
    C.W.R.J. Cremers, P.G.A.B. Wijdeveld, A.J.L.G. Pinckers, Juvenile diabetes mellitus, optic atrophy, hearing loss, diabetes insipidus, atonia of the urinary tract and bladder, and other abnormalities (WOLFRAM SYNDROME). Acta Paediatr. 66(s264), 1–16 (1977).  https://doi.org/10.1111/j.1651-2227.1977.tb15069.x CrossRefGoogle Scholar
  17. 17.
    I. Bernabeu, R. Cámara, R. Araujo et al. Descripción del síndrome de Wolfram (DIDMOAD) a partir de un nuevo caso. Rev. Clin. Esp. 184, 418–20 (1989)Google Scholar
  18. 18.
    B. Kinsley, M. Swift, R. Dumont, R. Swift, Morbidity and mortality in the wolfram syndrome. Diabetes Care 18, (1995).  https://doi.org/10.2337/diacare.18.12.1566
  19. 19.
    A. Cano, L. Molines, R. Valéro, G. Simonin, V. Paquis-Flucklinger, B. Vialettes, Microvascular diabetes complications in wolfram syndrome (Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, and Deafness [DIDMOAD]). Diabetes Care 30, (2007).  https://doi.org/10.2337/dc07-0380
  20. 20.
    M. Dreyer, H. Rüdiger, K. Bujara et al. The syndrome of diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and other abnormalities (DIDMOAD-Syndrome). Klin. Wochenschr. 60, 471–5 (1982)CrossRefPubMedGoogle Scholar
  21. 21.
    Project E-W. Management of Wolfram Syndrome a Clinical Guideline. Wolfram Syndrome Guideline Development Group. (2014). http://www.euro-wabb.org/images/eurowabb/guidelines/Wolfram_guideline_V14_ 28_04_2014.pdfGoogle Scholar
  22. 22.
    J. Rohayem, C. Ehlers, B. Wiedemann et al. Diabetes and neurodegeneration in Wolfram syndrome A multicenter study of phenotype and genotype. Diabetes Care 34, 1503–10 (2011).  https://doi.org/10.2337/dc10-1937 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Clinical Management Unit Garrucha, Area of Health Management North of AlmeríaSpanish Association for Research and Help to Wolfram SyndromeGarruchaSpain
  2. 2.Andalusian Public Foundation for the Biosanitary Research of Eastern Andalusia-Alejandro OteroSpanish Association for Research and Help to Wolfram SyndromeAndaluciaSpain
  3. 3.CIBERNEDDonostia University Hospital Neurology Service Area of Neurosciences Biodonostia Research InstituteSan SebastianSpain
  4. 4.Endocrinology and Nutrition UnitRafael Méndez HospitalGranadaSpain
  5. 5.Clinical Management Unit, Internal Medicine Hospital La InmaculadaArea of Health Management North of AlmeríaAlmeríaSpain

Personalised recommendations